Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Public Alerted to Counterfeit Glucose Test Strips
In October, the FDA notified Americans that counterfeit blood glucose test strips are being sold in the United States for use with various models of LifeScan, Inc., One Touch Brand Blood Glucose Monitors used by diabetics to measure their blood glucose. The FDA said the counterfeit test strips could give incorrect blood glucose values, which could lead a patient to take the wrong dosage of insulin. The agency recommends that all counterfeit products be discarded. The counterfeit test strips are: 1) One Touch Basic'/Profile' (lot #272894A, 2619932 or 2606340) test strips that are in 50-Count packages that include text on their boxes in English, Greek and Portuguese; and, 2) One Touch Ultra' (lot #2691191) test strips in 50-Count packages with carton text in both English and French.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.